BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 34,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00. Following the completion of the transaction, the chief executive officer owned 519,209 shares in the company, valued at $51,194,007.40. The trade was a 6.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Price Performance

BNTX stock opened at $96.06 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The business has a 50 day simple moving average of $97.38 and a 200-day simple moving average of $94.93. The firm has a market capitalization of $24.29 billion, a PE ratio of -12.27 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.60) EPS. Equities research analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC increased its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after purchasing an additional 506 shares during the period. Vestcor Inc acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $153,000. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of BioNTech by 328.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after purchasing an additional 1,423 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday. Canaccord Genuity Group dropped their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. UBS Group restated a “buy” rating on shares of BioNTech in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. Finally, BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.